Key result
Routine thromboprophylaxis with apixaban in myeloma patients treated with IMiD-containing regimens resulted in no venous thromboembolism and a 2.9% rate of arterial thrombosis at 6 months.
Why the study?
Does apixaban prevent arterial or venous thromboembolism in myeloma patients treated with IMiD-containing regimens?
Population
70 consecutive myeloma patients undergoing first-line therapy with immunomodulatory drug-containing…
Design
Cohort
Follow-up
6 months
Authors
Loading...
May support routine DOAC prophylaxis in IMiD-treated myeloma; extends VTE treatment evidence to prevention.
Observational (n=70)
No
Does apixaban prevent arterial or venous thromboembolism in myeloma patients treated with IMiD-containing regimens?
Routine thromboprophylaxis with apixaban in myeloma patients receiving IMiD-containing regimens is associated with very low rates of venous and arterial thrombosis and a low risk of major bleeding.
Storrar et al. (2018) conducted an observational in Multiple myeloma (n=70). Apixaban was evaluated on Occurrence of arterial or venous thromboembolism within 6 months of treatment initiation. Routine thromboprophylaxis with apixaban in myeloma patients treated with IMiD-containing regimens resulted in no venous thromboembolism and a 2.9% rate of arterial thrombosis at 6 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: